# US 2010/0303838 A1 · Vectors for multiple gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303838 A1
- Document ID: US20100303838A1
- Status: Published application
- Kind: A1
- Application number: 12/599,971
- Filed: 2008-01-29
- Published: 2010-12-02
- Earliest claimed: 2007-05-15
- Assignees: Transgene S.A.
- Inventors: Nathalie Silvestre; Doris Schmitt
- Web page: https://patentgrep.com/patent/US20100303838A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2840/20: translation of more than one cistron
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a vector for expressing at least a first and a second nucleic acid molecules which exhibit a percentage of homology of approximately 80% or greater than 80% over a portion of 40 or more continuous nucleotides and wherein said first nucleic acid molecule and/or said second nucleic acid molecule is modified so as to reduce said percentage of homology to less than 75%. The present invention also relates to substantially isolated nucleic acid molecules comprising a nucleotide sequence as defined in any of SEQ ID NO: 9-15 and 66-69. It also provides a host cell and a pharmaceutical composition comprising such a nucleic acid molecule or vector as well as their use for therapeutic or preventive purposes.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A vector comprising at least a first nucleic acid molecule encoding a first polypeptide and a second nucleic acid molecule encoding a second polypeptide wherein:
said first and second nucleic acid molecules are obtained respectively from a first and second native nucleic acid sequences which exhibit a percentage of homology of approximately 80% or greater than 80% over a portion of 40 or more continuous nucleotides;
said first nucleic acid molecule and/or said second nucleic acid molecule are modified so as to reduce the percentage of homology to less than 75%; and
said first nucleic acid molecule and said second nucleic acid molecule encode at least the same polypeptide obtained from closely related HPV serotypes.

### Claim 31 (depends on 30)

The vector according to claim 30, wherein the codon usage pattern of the first nucleic acid molecule and/or the second nucleic acid molecule is modified at least in said homologous portion(s) of 40 or more continuous nucleotides so as to reduce the percentage of homology to less than 75%.

### Claim 32 (depends on 31)

The vector according to claim 31, wherein the codon usage pattern is modified at the nucleotide level and said modifications are silent at the amino acid level.

### Claim 33 (depends on 30)

The vector according to claim 30, wherein the codon usage pattern is modified in such a way that homologous portions between the first and second nucleic acid molecules are restricted to less than 8 consecutive nucleotides.

### Claim 34 (depends on 33)

The vector according to claim 33, wherein the codon usage pattern is modified in such a way that homologous portions between the first and second nucleic acid molecules are restricted to less than 5 consecutive nucleotides.

### Claim 35 (depends on 30)

The vector according to claim 30, wherein said vector is an adenoviral vector.

### Claim 36 (depends on 35)

The vector according to claim 35, wherein said adenoviral vector is replication-defective.

### Claim 37 (depends on 30)

The vector according to claim 30, wherein said vector is a poxviral vector.

### Claim 38 (depends on 37)

The vector according to claim 37, wherein said poxviral vector is obtained from a vaccinia virus selected from the group consisting of the Copenhagen strain, the Wyeth strain, NYVAC and the highly attenuated modified Ankara (MVA) stain.

### Claim 39 (depends on 30)

The vector according claim 30, wherein the first and second nucleic acid molecules are independently obtained from a high risk papillomavirus selected from the group consisting of HPV-16, HPV-18, HPV-30, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-66, HPV-68, HPV-70 and HPV-85.

### Claim 40 (depends on 39)

The vector according to claim 39, wherein the first and second nucleic acid molecules encode an early papillomavirus polypeptide selected from the group consisting of E1, E2, E6 and E7.

### Claim 41 (depends on 30)

The vector according to claim 30, wherein said same polypeptide obtained from closely related organisms is an E2 polypeptide.

### Claim 42 (depends on 30)

The vector according to claim 30, wherein said closely related HPV serotypes are selected from the group consisting of HPV-16, HPV-18, HPV-33, HPV-52, and combinations thereof.

### Claim 43 (depends on 42)

The vector according to claim 42, wherein said vector comprises a first nucleic acid molecule encoding an HPV-16 E2 polypeptide, a second nucleic acid molecule encoding an HPV-18 E2 polypeptide, a third nucleic acid molecule encoding an HPV-33 E2 polypeptide, and a fourth nucleic acid molecule encoding an HPV-52 E2 polypeptide.

### Claim 44 (depends on 43)

The vector according to claim 43, wherein said HPV-16 E2 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 7, said HPV-18 E2 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 8, said HPV-33 E2 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 70 and said HPV-52 E2 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 71.

### Claim 45 (depends on 43)

The vector according to claim 43, wherein said first nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 12; said second nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 13; said third nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 67 and said fourth nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 69.

### Claim 46 (depends on 30)

The vector according to claim 30, wherein said same polypeptide obtained from closely related organisms is an E6 polypeptide, an E7 polypeptide or both E6 and E7 polypeptides.

### Claim 47 (depends on 46)

The vector according to claim 46, wherein the first nucleic acid molecule encodes an HPV-16 E6 polypeptide and the second nucleic acid molecule encodes an HPV-18 E6 polypeptide, and wherein the second nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 14.

### Claim 48 (depends on 46)

The vector according to claim 46, wherein the first nucleic acid molecule encodes an HPV-16 E7 polypeptide and the second nucleic acid molecule encodes an HPV-18 E7 polypeptide, and wherein the second nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 15.

### Claim 49 (depends on 47)

The vector according to claim 47, wherein said vector is a MVA vector, the first nucleic acid molecule is placed under the control of the vaccinia 7.5K promoter, the second nucleic acid molecule is placed under the control of the vaccinia H5R promoter, and the first and second nucleic acid molecules are both inserted in deletion III of said MVA vector.

### Claim 50 (depends on 46)

The vector according to claim 46, wherein said vector comprises a first nucleic acid molecule encoding an HPV-16 E6 polypeptide, a second nucleic acid molecule encoding an HPV-18 E6 polypeptide, a third nucleic acid molecule encoding an HPV-16 E7 polypeptide and a fourth nucleic acid molecule encoding an HPV-18 E7 polypeptide wherein said first, second, third and fourth nucleic acid molecules do not comprise a portion of 40 or more continuous nucleotides exhibiting a percentage of homology of 75% or greater than 75%.

### Claim 51

A substantially isolated nucleic acid molecule comprising the nucleotide sequence shown in any of SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 66, 67, 68 or 69.

### Claim 52 (depends on 30)

A host cell comprising the vector according to claim 30.

### Claim 53 (depends on 30)

A pharmaceutical composition comprising a therapeutically effective amount of the vector according to claim 30 and a pharmaceutically acceptable vehicle.

### Claim 54 (depends on 53)

The pharmaceutical composition of claim 53, wherein said composition comprises one or more adjuvant suitable for systemic or mucosal administration in humans.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein said adjuvant is an imidazoquinoline compound.

### Claim 56 (depends on 30)

A method for treating or preventing infectious disease, cancer or immune deficiency disease, comprising administering an effective amount of the vector of claim 30 to a subject in need thereof.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the infectious disease comprises infection by a papillomavirus.

### Claim 58 (depends on 56)

The method according to claim 56, wherein the method is carried out according to a prime boost therapeutic modality and wherein said vector is used to prime and/or boost an immune response in a subject.
